A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT02277392 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Ovarian, Fallopian Tube and Peritoneal Cancer

Interventions

BIOLOGICAL: Vaccine---primed, CD3/CD28---costimulated autologous peripheral blood T---cells
BIOLOGICAL: SB---485232 (Human recombinant Interleukin---18)

Sponsor

Abramson Cancer Center at Penn Medicine